The pharmacological properties of triptorelin and its mode of administration make accidental or intentional overdosage unlikely. There were no reported overdoses in clinical trials. In single dose toxicity studies in mice and rats, the subcutaneous LD50 of triptorelin was 400 mg/kg in mice and 250 mg/kg in rats, approximately 7000 and 4000 times, respectively, the usual human dose. If overdosage occurs however, therapy should be discontinued immediately and the appropriate supportive and symptomatic treatment administered.

TRELSTAR^TM DEPOT is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, other LHRH agonists or LHRH. Three postmarketing reports of ana-phylactic shock and seven postmarketing reports of angioedema related to triptorelin administration have been reported since 1986 (see WARNINGS).

TRELSTAR^TM DEPOT may cause fetal harm when administered to a pregnant woman.

Bookmark this page: